← Changchun High & New Technology Industries overview

Changchun High & New Technology Industries vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Changchun High & New Technology Industries Group Inc (000661.CS)

Q3 2026
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

August 2026
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

Latest
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.